Opendata, web and dolomites

MYODM-FSMP SIGNED

New food for special medical purposes to nutritionally manage Myotonic Dystrophy type 1

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MYODM-FSMP project word cloud

Explore the words cloud of the MYODM-FSMP project. It provides you a very rough idea of what is the project "MYODM-FSMP" about.

methylxanthines    disclosed    behind    launching    solution    sustainable    myogem    certain    multisystemic    patients    people    property    dystrophy    goals    soe    cohort    wo2016075288    awarded    de    dietary    million    clinical    fsmp    patents       medical    munain    perform    overcome    food    small    oacute    feasibility    faces    life    human    disease    licensee    neuromuscular    special    ends    either    sponsored    consume    patient    neurologists    rare    claim    myotonic    first    data    confidence    prescribe    upgrade    suffer    specialized    acute    foods    citizens    compile    community    wo2016075285    supplement    rights    individuals    15    som    treatment    option    commitment    gain    advantages    supplements    pilot    intellectual    purposes    leave    drugs    intended    pez    barrier    evidences    broadly    associations    diseases    2017    light    myodm    effect    owning    company    cure    neurologist    adolfo    competitive    dr    launched    a1    quality    leaded    worldwide    commercially    dm1    purpose    trial    market   

Project "MYODM-FSMP" data sheet

The following table provides information about the project.

Coordinator
MYOGEM HEALTH COMPANY SL 

Organization address
address: C/ALVAREZ DE CASTRO, 63
city: MOLLET DEL VALLES
postcode: 8100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MYOGEM HEALTH COMPANY SL ES (MOLLET DEL VALLES) coordinator 50˙000.00

Map

 Project objective

Myotonic Dystrophy type 1 (DM1) is the most common and multisystemic neuromuscular rare disease affecting 1 million people worldwide, 100,000 EU citizens, who still have no cure or treatment available. In the light of the ´Leave No-one Behind´ commitment behind Sustainable Development Goals and particularly, the dietary management approach may provide a unique option for rare disease patients through Foods for special medical purposes (FSMP), foods (not drugs) intended for the dietary management of individuals who suffer from certain diseases. The main goal of the present project is to compile in human evidences that MYODM’s food for special medical purposes is a unique approach to improve DM1 patients’ Quality of Life through a pilot clinical trial for foods and supplements sponsored by Myogem and leaded by Dr. Adolfo López de Munain, a worldwide neurologist specialized in DM1. MYOGEM is the current licensee of the patents WO2016075288 A1 and WO2016075285 A1, which disclosed the effects of some methylxanthines on DM1. Owning the Intellectual Property Rights over the present solution is one of the main competitive advantages of MYOGEM. MYOGEM is the first and unique company worldwide who launched a food supplement for a rare disease in May 2017. However, as food supplement MYODM faces the problem that DM1 community, either neurologists and patient associations, claim for in human data in order to broadly prescribe and consume the product. To overcome this barrier, and gain market confidence, MYOGEM aims to perform a Feasibility pilot clinical trial to demonstrate MYODM’s effect on a small cohort of 10-15 DM1 patients in order to commercially upgrade our current product “food supplement” to “food for special medical purpose”, from now on referred as MYODM-FSMP, that will reach the market in less than one year after the present project ends. By launching the new MYODM-FSMP product, a 5.5 M€ SOM is expected in 5 years after the project. Two SoE have been awarded.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYODM-FSMP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MYODM-FSMP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

STURSKIN (2018)

Innovative products by using tanned sturgeon skin

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More